



ORIGINAL RESEARCH ARTICLE

Awareness of Smoking Cessation Aids in Heart Disease Patients at Governmental Hospitals

Hanin Bogari*, Raghad Althubaiti, Ghaidaa Garoot and Asmaa Ali

Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia

*Corresponding author: Hanin Bogari, Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia



Abstract

Background: Over one million people are smoking worldwide and the total numbers is expected to increase each year [1]. Several studies have shown a relation between smoking and heart problems, which highlight special consideration in smoking cessation awareness in heart disease patients with established vascular disease as a secondary prevention.

Objective: To evaluate the current awareness of smoking cessation products in heart disease patients at governmental hospitals in Jeddah.

Methods:

Design: Cohort structured questionnaire-based interview was held.

Settings: Tertiary governmental hospitals.

Patients: Heart disease patients who are following up in cardiology clinics in governmental hospitals in Jeddah.

Main outcome measures: Awareness of smoking cessation products and its usage.

Results: 150 patients were interviewed. 19% (n = 28) were smokers, 2% (n = 3) returned to smoke (31 are active smokers), 56% (n = 85) non-smoker and 23% (n = 34) quit smoking. Their average age is 60 ± 5 years and 70% (n = 105) of the patients were males. Regarding the level of awareness of the availability of smoking cessation products 32.2% (n = 47) of the patients were aware of the nicotine patch, 30.2% (n = 44) of patients were aware of nicotine gum, 18.1% (n = 26) of patients were aware of nicotine lozenge, 7.4% (n = 11) of patients were aware of varenicline (Chantix®), 1.3% (n = 2) of the patients were aware of cystisine and only 0.7% (n = 1) were aware of bupropion HCl. The motivators for quitting smoking in 65 of the smokers (actively smoking and patients who quit smoking) were 36% (n = 21) for self-motivation, 34% (n = 20)

for physicians, 25% (n = 15) for family members and 5% (n = 3) for friends. And out of 65 patients (actively smoking and patients who quit smoking) only 10.8% (n = 7) visited smoking cessation clinic.

Conclusion: The poor awareness of the smoking cessation products shown in this study, suggests that strategies of support and control are urgently needed especially in heart disease patients with underline high risk.

Keywords

Smoking cessation, Heart disease, Quit, Awareness, Governmental hospitals

Introduction

The World Health Organization described tobacco smoking as an epidemic, with an expectation of three million deaths yearly, worldwide, because of smoking. This figure is expected to rise to ten million a year by the years 2020s or early 2030s, if the current states of smoking continue. The developing countries will have seventy percent deaths due to smoking [2].

Smoking has long been associated with preventable morbidity and premature death in human population [3]. Several studies have shown a relation between smoking and lung cancer, coronary heart disease, chronic obstructive pulmonary disease, stroke and polycythemia [4].

Smoking damages the lining of the arteries, leading to a buildup of fatty material (atheroma) which narrows the artery. This can cause angina, a heart attack or a stroke. The carbon monoxide in tobacco smoke reduces

the amount of oxygen in the blood. Which highlight special consideration in smoking cessation awareness in heart disease patients with established vascular disease as a secondary prevention [5].

The Saudi Smoking Control Charitable Society, over the last fourteen years, has built 33 smoking cessation clinics all over the country. The visits rates of these clinics are limited, with a quitting rate of 13% [6]. However, this figure should be clarified with caution, since there is no accurate data on the duration of follow up and the relapse rate.

Methods

Consecutive attenders at a routine cardiac clinics in Jeddah of large governmental hospitals which are King Abdulaziz University Hospital, King Fahad Hospital and King Abdulaziz Medical City -Cardiology center- were approached, and interviewed whether they were current cigarette smokers or not. A structured questionnaire interview was held with 150 current patients attending cardiology clinics. Data collection included age, sex, type of heart disease, presence of hyperlipidemia, smoking status, their knowledge about the availability of the smoking cessation products which are varenicline (Chantix®), cystisine (Tabex®), nicotine lozenge, nicotine Patch (Quit4®, Equate®, Polacrilex®, Nicotinell®) and nicotine gum (Equate®, Polacrilex®, Nicorette®). They were all asked on a person-to-person basis, who filled in the appropriate answers on the form. More data were collected in smokers including number of cigarettes per day, duration of smoking, their willing to quit smoking, difficulty of smoking cessation, knowledge about the smoking cessation clinics around, methods used for quitting, reason of trying to quit and if the patient has used any medication to help quitting.

Results

150 questionnaires were filled and the baseline characteristic of heart disease patients (Table 1) include

70% (n = 105) males and the average age of the patients were 60 ± 5 years, the type of heart diseases include 42% (n = 69) of patients had hypertension, 18% (n = 30) of patients had cardiovascular disease, 11% (n = 18) of patients had cardiomyopathy, 11% (n = 18) of patients had angina pectoris, 11% (n = 18) of patients had valvular heart disease, 5% (n = 8) of patients had arrhythmia, 1% (n = 2) of the patients had pericarditis presented and 1% (n = 2) of patients had myocarditis (Figure 1).

In 150 Cardiac patients 19% (n = 28) were smokers, 2% (n = 3) returned to smoke (31 are active smokers), 56% (n = 85) non-smoker and 23% (n = 34) quit smoking (Figure 2). The Awareness of smoking risk on the heart was 89.3% (n = 134) in the heart disease patients.

The consumption of cigarette in the 65 patients (actively smoking and patients who quit smoking) showed that 57% (n = 37) of the patients consume packet or more per day which is the most consumed amount, 22% (n = 14) of the patients consume less than 5 cigarettes per day, 12% (n = 8) of the patients consume 16 ± 3 cigarettes per day and 9% (n = 6) of the

Table 1: The baseline characteristics.

Characteristics	Number of patients (n = 150)
Sex	70% (n = 105) males
Age (years)	60 ± 5
Type of heart disease:	
• Hypertension	42% (n = 69)
• Cardiovascular disease	18% (n = 30)
• Cardiomyopathy	11% (n = 18)
• Angina Pectoris	11% (n = 18)
• Valvular heart disease	11% (n = 18)
• Arrhythmia	5% (n = 8)
• Pericarditis	1% (n = 2)
• Myocarditis	1% (n = 2)
Hyperlipidemia	50.6% (n = 71)




Figure 1: Type of heart disease.




Figure 2: Status of the patients.




Figure 3: Amount of cigarettes smoked daily by the heart disease patients.




Figure 4: Willingness to quit smoking.




patients consume 9 ± 3 cigarettes (Figure 3). Patients' awareness of smoking risk on the heart was 89.33% ($n = 134$). The intention to quit smoking was in 76.9% ($n = 50$) of the smokers, though 52% ($n = 34$) of the patients succeeded in quitting, 25% ($n = 16$) returned to smoke and 23% ($n = 15$) of the patients were not willing to quit (Figure 4). The percentage of smokers who visited smoking cessation clinic was only 10.8% ($n = 7$).

Regarding the patients who quit smoking ($n = 34$); the withdrawal symptoms during the quitting interval were, 25% ($n = 22$) of patients had anxiety which is the most prevalent symptom, 15% ($n = 13$) had

headache, 13% ($n = 11$) had depression, 13% ($n = 11$) had sleep disturbance, 24% ($n = 21$) had not suffered from any problems and 11% ($n = 10$) had difficulty in quitting smoking due to environmental factors (Figure 5). Regarding the level of awareness of the availability of smoking cessation products 32.2% ($n = 47$) of the patients were aware of the nicotine patch, 30.2% ($n = 44$) of patients were aware of nicotine gum, 18.1% ($n = 26$) of patients were aware of nicotine lozenge, 7.4% ($n = 11$) of patients were aware of varlenicline) Chantix®, 1.3% ($n = 2$) of the patients were aware of cystisine and only 0.7% ($n = 1$) were aware of bupropion HCl. 10.8% ($n = 4$) of the quitters used smoking cessation products;

Table 2: The level of awareness of the availability and percentage of usage of smoking cessation aids.

Product name	% of awareness of availability in the 150 patients	% of usage in the 65 patients
Varenicline (Champix®-Chantix®)	7.4	4.6
Bupropion HCl (Wellbutrin®)	0.7	-
Cystisine (Tabex®)	1.3	-
Nicotine Lozenge (Quit 4®-Equate®-Polacrilex®-Nicotinell®)	18.1	3
Nicotine Patch (Nicotinell®-Nicodream CQ®)	32.2	4.6
Nicotine Gum (Equate®-Polacrilex®-Nicorette®)	30.2	1.5

**Figure 5:** Withdrawal symptoms.**Figure 6:** Time since quitting in years.**Figure 7:** The motivators for quitting smoking in the 65 smokers.

where 4.6% (n = 3) used nicotine patch, 3% (n = 2) used nicotine lozenge, 1.5% (n = 1) used varenicline (Chantix®) and 1.5% (n = 1) nicotine gum (Table 2).

Regarding the time since they quit smoking 18% (n = 6) of the smokers quit within 5 years ago, 61% (n = 20) quit more than 5 years ago and 21% (n = 7) quit in less than 1 year ago (Figure 6). The motivators

for quitting smoking in 65 of the smokers (actively smoking and patients who quitted smoking) were 36% (n = 21) for self-motivation, 34% (n = 20) for physicians, 25% (n = 15) for family members and 5% (n = 3) for friends (Figure 7).

Discussion

Our survey confirms some levels of unawareness of smoking cessation aids. Only 42.6% (n = 64) of the 150 heart disease patients are aware of the availability of smoking cessation pharmacotherapeutic products (Table 2).

The awareness of smoking cessation products reported in this study was compared with the results of GV Gill, et al. study about the awareness and use of smoking cessation treatments among diabetic patients (2004). The mean cigarette consumption per day was lower than our study which is 16/day.

Regarding the awareness of the medications used in smoking cessation in the GV Gill, et al. research 34% had never heard of the nicotine replacement therapy (NRT) which is Lower than our study which is 60.66% (n = 91). For bupropion; it was unknown to 46% of the patients while in our study 99.3% (n = 149) of the patients were unaware of this product. 8% of the diabetic patients had used the NHS Quitline services compared to the percentage of the heart disease smokers who visited smoking cessation clinic in our study which was 10.8% [7].

The limitations we faced during the research are limited time for data collection, small sample size and some patients refused the survey.

Conclusion

The poor awareness of the smoking cessation products shown in this study, suggests that strategies of support and control are urgently needed especially in heart disease patients with underline high risk.

Funding

None.

Authors Contribution

All authors have contributed to the work and manuscript writing equally.

References

1. Haseebullah, Almotairi M (2012) Smoking in Saudi Arabia and its control measures. *British Journal of Humanities and Social Sciences* 5: 69-75.
2. Byrd JC, Shapino RS, Schiedermayer DL (1985) Smoking: Health effects and control. *N Engl J Med* 8: 31-491.
3. Bornstein MM, Frei M, Sendi P, Ramseier CA, Reichart PA (2012) Patients' awareness of the potential benefit of smoking cessation. A study evaluating self-reported and clinical data from patients referred to an oral medicine unit. *Clin Oral Investig* 16: 55-62.
4. Didkowska J, Wojciechowska U, Mańczuk M, Łobaszewski J (2016) Lung cancer epidemiology: Contemporary and future challenges worldwide. *Ann Transl Med* 4: 150.
5. Rockville MD (2014) The health consequences of smoking - 50 years of progress: A report of the surgeon general. Department of Health and Human Services, Centers for Disease Control and Prevention.
6. Doll R, Hill AB (1950) Smoking and carcinoma of the lung. *Br Med J* 2: 739-748.
7. Gill GV, Morgan C, MacFarlane IA (2005) Awareness and use of smoking cessation treatments among diabetic patients. *Diabet Med* 22: 658-660.